As filed with the Securities and Exchange Commission
on March 11, 2024
Registration No. 333-_____
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
OCULAR THERAPEUTIX, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware |
20-5560161 |
(State or Other Jurisdiction of Incorporation
or Organization) |
(I.R.S. Employer
Identification No.) |
|
|
15 Crosby Drive
Bedford, MA |
01730 |
(Address of Principal Executive Offices) |
(Zip Code) |
2014 Employee Stock Purchase Plan
(Full Title of the Plan)
Antony Mattessich
President and Chief Executive Officer
Ocular Therapeutix, Inc.
15 Crosby Drive
Bedford, MA 01730
(Name and Address of Agent for Service)
(781) 357-4000
(Telephone Number, Including Area Code, of Agent
for Service)
Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions
of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging
growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
¨ |
Accelerated filer |
¨ |
Non-accelerated filer |
x |
Smaller reporting company |
x |
|
|
Emerging Growth Company |
¨ |
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. o
EXPLANATORY NOTE
This Registration Statement on Form S-8, relating to 207,402 shares
of the common stock, $0.0001 par value per share (the “Common Stock”), issuable under the 2014 Employee Stock Purchase Plan,
as amended (the “2014 ESPP”) of Ocular Therapeutix, Inc. (the “Registrant”), is being filed for the purpose of
registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 has previously
been filed and is effective. Accordingly, this Registration Statement incorporates by reference the contents of (i) the Registration Statement
on Form S-8 (File No. 333-198240) filed with the Securities and Exchange Commission (the “SEC”) on August 19, 2014, by the
Registrant relating to the Registrant’s 2006 Stock Incentive Plan, as amended, the Registrant’s 2014 Stock Incentive Plan
(the “2014 Plan”), and the 2014 ESPP; (ii) the Registration Statement on Form S-8 (File No. 333-202886) filed with the SEC on March 20, 2015, by the Registrant relating to the 2014 Plan and the 2014 ESPP; (iii) the Registration Statement on Form S-8 (File No. 333-210059) filed with the SEC on March 10, 2016, by the Registrant relating to the 2014 Plan and the 2014 ESPP; (iv) the Registration
Statement on Form S-8 (File No. 333-216622) filed with the SEC on March 10, 2017, by the Registrant relating to the 2014 Plan and the
2014 ESPP; (v) the Registration Statement on Form S-8 (File No. 333-223513) filed with the SEC on March 8, 2018, by the Registrant relating
to the 2014 Plan, the 2014 ESPP and the Registrant’s Inducement Stock Option Grant to Antony Mattessich; (vi) the Registration Statement
on Form S-8 (File No. 333-230126) filed with the SEC on March 7, 2019, by the Registrant relating to the 2014 Plan and the 2014 ESPP;
(vii) the Registration Statement on Form S-8 (File No. 333-237115) filed with the SEC on March 12, 2020, by the Registrant relating to
the 2014 Plan, the 2014 ESPP, the Registrant’s Inducement Stock Option Grant to Christopher White and the Registrant’s 2019
Inducement Stock Incentive Plan (the “2019 Inducement Plan”); (viii) the Registration Statement on Form S-8 (File No. 333-254143) filed with the SEC on March 11, 2021, by the Registrant relating to the 2014 Plan, the 2014 ESPP and the 2019 Inducement Plan; (ix) the
Registration Statement on Form S-8 (File No. 333-263091) filed with the SEC on February 28, 2022, by the Registrant relating to the 2014
ESPP; and (x) the Registration Statement on Form S-8 (File No. 333-270297) filed with the SEC on March 6, 2023, by the Registrant relating
to the 2014 ESPP, in each case, except to the extent amended or superseded by the contents hereof and, in the case of items (i) through
(viii) above, as amended by Post-Effective Amendment No. 1 to Form S-8 Registration Statements relating to such Form S-8 Registration Statement, filed with the SEC on August 9, 2021.
Item 8. Exhibits.
The following exhibits are incorporated herein by reference.
Number |
Description |
|
|
4.1(1) |
Restated Certificate of Incorporation of the Registrant, as amended |
|
|
4.2(2) |
Amended and Restated By-laws of the Registrant |
|
|
4.3(3) |
Registration Rights Agreement, dated as of March 1, 2019, by and among the Registrant and the Purchasers identified therein |
|
|
4.4(4) |
Registration Rights Agreement, dated February 21, 2024, by and among the Registrant and the other parties thereto |
|
|
5.1 |
Opinion of Wilmer Cutler Pickering Hale and Dorr LLP |
|
|
23.1 |
Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1) |
|
|
23.2 |
Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm |
|
|
24.1 |
Power of Attorney (included on signature page) |
|
|
99.1(5) |
2014 Employee Stock Purchase Plan |
|
|
99.2(6) |
Amendment No. 1 to Employee Stock Purchase Plan, effective October 4, 2023 |
|
|
107 |
Filing Fee Table |
| (1) | Previously filed with the Securities and Exchange Commission on August 9, 2021, as Exhibit 3.1 to the Registrant’s Quarterly
Report on Form 10-Q (File No. 001-36554) and incorporated herein by reference. |
| (2) | Previously filed with the Securities and Exchange Commission on July 30, 2014, as Exhibit 3.2 to the Registrant’s Current Report
on Form 8-K (File No. 001-36554) and incorporated herein by reference. |
| (3) | Previously filed with the Securities and Exchange Commission on March 7, 2019, as Exhibit 4.2 to the Registrant’s Annual Report
on Form 10-K (File No. 001-36554) and incorporated herein by reference. |
| (4) | Previously filed with the Securities and Exchange Commission on February 22, 2024, as Exhibit 10.2 to the Registrant’s Current
Report on Form 8-K (File No. 001-36554) and incorporated herein by reference. |
| (5) | Previously filed with the Securities and Exchange Commission on July 11, 2014, as Exhibit 10.10 to Amendment No. 1 to the Registrant’s
Registration Statement on Form S-1 (File No. 333-196932) and incorporated herein by reference. |
| (6) | Previously filed with the Securities and Exchange Commission on November 7, 2023, as Exhibit 10.3 to the Registrant’s Quarterly
Report on Form 10-Q (File No. 001-36554) and incorporated herein by reference. |
SIGNATURES
Pursuant to the requirements of the Securities
Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for
filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized,
in Bedford, Massachusetts, on this 11th day of March, 2024.
OCULAR THERAPEUTIX, INC. |
|
|
|
By: |
/s/ Antony Mattessich |
|
|
Antony Mattessich |
|
|
President and Chief Executive Officer |
|
POWER OF ATTORNEY AND SIGNATURES
We, the undersigned officers and directors of Ocular
Therapeutix, Inc., hereby severally constitute and appoint Antony Mattessich and Donald Notman, and each of them singly, our true and
lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below,
the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally
to do all such things in our names and on our behalf in our capacities as officers and directors to enable Ocular Therapeutix, Inc. to
comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission,
hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement
and any and all amendments thereto.
Pursuant to the requirements of the Securities
Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
Signature |
|
Title |
|
Date |
|
|
|
|
|
|
|
/s/ Antony Mattessich |
|
President, Chief Executive Officer and Director (Principal Executive Officer) |
|
March 11, 2024 |
|
Antony Mattessich |
|
|
|
|
|
|
|
|
|
/s/ Donald Notman |
|
Chief Financial Officer (Principal Financial and Accounting Officer) |
|
March 11, 2024 |
|
Donald Notman |
|
|
|
|
|
|
|
|
|
/s/ Pravin Dugel, M.D. |
|
Executive Chairman of the Board of Directors |
|
March 11, 2024 |
|
Pravin Dugel, M.D. |
|
|
|
|
|
|
|
|
|
|
|
/s/ Adrienne Graves, Ph.D. |
|
Director |
|
March 11, 2024 |
|
Adrienne Graves, Ph.D. |
|
|
|
|
|
|
|
|
|
|
|
/s/ Seung Suh Hong, Ph.D. |
|
Director |
|
March 11, 2024 |
|
Seung Suh Hong, Ph.D. |
|
|
|
|
|
|
|
|
|
|
|
/s/ Richard L. Lindstrom, M.D. |
|
Director |
|
March 11, 2024 |
|
Richard L. Lindstrom, M.D. |
|
|
|
|
|
|
|
|
|
|
|
/s/ Merilee Raines |
|
Director |
|
March 11, 2024 |
|
Merilee Raines |
|
|
|
|
|
|
|
|
|
|
|
/s/ Charles Warden |
|
Director |
|
March 11, 2024 |
|
Charles Warden |
|
|
|
|
|
|
|
|
|
|
|
/s/ Leslie Williams |
|
Director |
|
March 11, 2024 |
|
Leslie Williams |
|
|
|
|
|
March 11, 2024
Ocular Therapeutix, Inc. 15 Crosby Drive Bedford, MA 01730
|
Exhibit 5.1
+ 1 617 526 6000 (t)
+ 1 617 526 5000 (f) |
| Re: | 2014 Employee Stock Purchase Plan |
Ladies and Gentlemen:
We have assisted in the preparation of a Registration Statement on
Form S-8 (the “Registration Statement”) to be filed with the Securities and Exchange Commission (the “Commission”)
under the Securities Act of 1933, as amended (the “Securities Act”), relating to an aggregate of 207,402 shares of common
stock, $0.0001 par value per share (the “Shares”), of Ocular Therapeutix, Inc., a Delaware corporation (the “Company”),
issuable under the Company’s 2014 Employee Stock Purchase Plan, as amended (the “Plan”).
We have examined the Certificate of Incorporation and By-laws of the
Company, each as amended and restated to date, and originals, or copies certified to our satisfaction, of all pertinent records of the
meetings of the board of directors and stockholders of the Company, the Registration Statement, the Plan and such other documents relating
to the Company as we have deemed material for the purposes of this opinion.
In our examination of the foregoing documents, we have assumed the
genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of
all documents submitted to us as certified, photostatic or other copies, the authenticity of the originals of any such documents and the
legal competence of all signatories to such documents.
We assume that the appropriate action will be taken, prior to the offer
and sale of the Shares in accordance with the Plan, to register and qualify the Shares for sale under all applicable state securities
or “blue sky” laws.
We express no opinion herein as to the laws of any state or jurisdiction
other than the General Corporation Law of the State of Delaware.
It is understood that this opinion is to be used only in connection
with the offer and sale of the Shares while the Registration Statement is in effect.
Ocular Therapeutix, Inc. March 11, 2024 Page 2 |
|
Please note that we are opining only as to the matters expressly set
forth herein, and no opinion should be inferred as to any other matters.
Based on the foregoing, we are of the opinion that the Shares have
been duly authorized for issuance and, when the Shares are issued and paid for in accordance with the terms and conditions of the Plan,
the Shares will be validly issued, fully paid and nonassessable.
We hereby consent to the filing of this opinion with the Commission
in connection with the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities
Act. In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of
the Securities Act or the rules and regulations of the Commission.
Very truly yours,
/s/ Wilmer Cutler Pickering Hale and Dorr LLP |
|
WILMER CUTLER PICKERING
HALE AND DORR LLP
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM
We hereby consent to the incorporation by reference in this Registration
Statement on Form S-8 of Ocular Therapeutix, Inc. of our report dated March 11, 2024 relating to the financial statements, which
appears in Ocular Therapeutix, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2023.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
March 11, 2024
Exhibit 107
Calculation of Filing Fee Tables
Form S-8
(Form Type)
Ocular Therapeutix, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1—Newly Registered Securities
Security
Type |
|
Security Class
Title |
|
Fee
Calculation
Rule |
|
Amount
Registered
(1) |
|
Proposed
Maximum
Offering
Price Per
Unit |
|
|
Maximum
Aggregate
Offering Price |
|
|
Fee Rate |
|
Amount of
Registration
Fee |
|
Equity |
|
Common Stock, $0.0001 par value per share |
|
Other |
|
207,402 shares (2) |
|
$ |
10.62 |
(3) |
|
$ |
2,202,609.24 |
(3) |
|
$147.60 per
$1,000,000 |
|
$ |
325.11 |
|
Total Offering Amounts |
|
|
|
$ |
2,202,609.24 |
|
|
|
|
$ |
325.11 |
|
Total Fee Offsets |
|
|
|
|
|
|
|
|
|
|
— |
|
Net Fee Due |
|
|
|
|
|
|
|
|
|
$ |
325.11 |
|
(1) |
In accordance with Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. |
(2) |
Consists of 207,402 shares issuable under the 2014 Employee Stock Purchase Plan, as amended. |
(3) |
Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act. The price per share and aggregate offering price are calculated on the basis of the average of the high and low sale prices of the registrant’s common stock on the Nasdaq Global Market on March 7, 2024, in accordance with Rule 457(c) under the Securities Act. |
Ocular Therapeutix (NASDAQ:OCUL)
過去 株価チャート
から 8 2024 まで 9 2024
Ocular Therapeutix (NASDAQ:OCUL)
過去 株価チャート
から 9 2023 まで 9 2024